Update on Janus Kinase Antagonists in Inflammatory Bowel Disease
- 24 June 2014
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 43 (3), 603-617
- https://doi.org/10.1016/j.gtc.2014.05.011
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysisClinical Rheumatology, 2013
- Host–microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseNature, 2012
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE SyndromeThe Journal of Pediatrics, 2012
- Inborn Errors of Human JAKs and STATsImmunity, 2012
- B-cell function in severe combined immunodeficiency after stem cell or gene therapy: A reviewJournal of Allergy and Clinical Immunology, 2010
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- Janus-Kinase-3-Dependent Signals Induce Chromatin Remodeling at the Ifng Locus during T Helper 1 Cell DifferentiationImmunity, 2008
- Unravelling the pathogenesis of inflammatory bowel diseaseNature, 2007